Update on amyloid‐β homeostasis markers for sporadic Alzheimer's disease

References

• Blennow K., de Leon M. J., Zetterberg H. Alzheimer's disease. Lancet 2006; 368: 387–403
   PubMed Web of Science ®Google Scholar
• De Strooper B. Aph‐1, Pen‐2, and Nicastrin with Presenilin generate an active gamma‐Secretase complex. Neuron 2003; 38: 9–12
   PubMed Web of Science ®Google Scholar
• Hussain I., Powell D., Howlett D. R., Tew D. G., Meek T. D., Chapman C., et al. Identification of a novel aspartic protease (Asp 2) as beta‐secretase. Mol Cell Neurosci 1999; 14: 419–27
   PubMed Web of Science ®Google Scholar
• Sinha S., Anderson J. P., Barbour R., Basi G. S., Caccavello R., Davis D., et al. Purification and cloning of amyloid precursor protein beta‐secretase from human brain. Nature 1999; 402: 537–40
   PubMed Web of Science ®Google Scholar
• Vassar R., Bennett B. D., Babu‐Khan S., Kahn S., Mendiaz E. A., Denis P., et al. Beta‐secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735–41
   PubMed Web of Science ®Google Scholar
• Yan R., Bienkowski M. J., Shuck M. E., Miao H., Tory M. C., Pauley A. M., et al. Membrane‐anchored aspartyl protease with Alzheimer's disease beta‐secretase activity. Nature 1999; 402: 533–7
   PubMed Web of Science ®Google Scholar
• Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605–13
   PubMed Web of Science ®Google Scholar
• Fukumoto H., Cheung B. S., Hyman B. T., Irizarry M. C. Beta‐secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 2002; 59: 1381–9
   PubMed Web of Science ®Google Scholar
• Johnston J. A., Liu W. W., Todd S. A., Coulson D. T., Murphy S., Irvine G. B., et al. Expression and activity of beta‐site amyloid precursor protein cleaving enzyme in Alzheimer's disease. Biochem Soc Trans 2005; 33: 1096–100
   PubMedGoogle Scholar
• Holsinger R. M., Lee J. S., Boyd A., Masters C. L., Collins S. J. CSF BACE1 activity is increased in CJD and Alzheimer disease versus corrected] other dementias. Neurology 2006; 67: 710–12
   PubMedGoogle Scholar
• Holsinger R. M., McLean C. A., Collins S. J., Masters C. L., Evin G. Increased beta‐Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann Neurol 2004; 55: 898–9
   PubMed Web of Science ®Google Scholar
• Verheijen J. H., Huisman L. G., van Lent N., Neumann U., Paganetti P., Hack C. E., et al. Detection of a soluble form of BACE‐1 in human cerebrospinal fluid by a sensitive activity assay. Clin Chem 2006; 52: 1168–74
   PubMed Web of Science ®Google Scholar
• Zhong Z., Ewers M., Teipel S., Burger K., Wallin A., Blennow K., et al. Levels of beta‐secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 2007; 64: 718–26
   PubMed Web of Science ®Google Scholar
• Zetterberg H., Andreasson U., Hansson O., Wu G., Sankaranarayanan S., Andersson ME., et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 2008; 65: 1102–7
   PubMed Web of Science ®Google Scholar
• Seubert P., Vigo‐Pelfrey C., Esch F., Lee M., Dovey H., Davis D., et al. Isolation and quantification of soluble Alzheimer's beta‐peptide from biological fluids. Nature 1992; 359: 325–7
   PubMed Web of Science ®Google Scholar
• Hock C., Golombowski S., Muller‐Spahn F., Naser W., Beyreuther K., Monning U., et al. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta‐peptide in Alzheimer's disease and major depression – inverse correlation with dementia severity. Eur Neurol 1998; 39: 111–18
   PubMed Web of Science ®Google Scholar
• Palmert M. R., Usiak M., Mayeux R., Raskind M., Tourtellotte W. W., Younkin S. G. Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease. Neurology 1990; 40: 1028–34
   PubMedGoogle Scholar
• Prior R., Monning U., Schreiter‐Gasser U., Weidemann A., Blennow K., Gottfries C. G., et al. Quantitative changes in the amyloid beta A4 precursor protein in Alzheimer cerebrospinal fluid. Neurosci Lett 1991; 124: 69–73
   PubMedGoogle Scholar
• Van Nostrand W. E., Wagner S. L., Shankle W. R., Farrow J. S., Dick M., Rozemuller J. M., et al. Decreased levels of soluble amyloid beta‐protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci USA 1992; 89: 2551–5
   PubMed Web of Science ®Google Scholar
• Lannfelt L., Basun H., Wahlund L. O., Rowe B. A., Wagner S. L. Decreased alpha‐secretase‐cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Nat Med 1995; 1: 829–32
   PubMedGoogle Scholar
• Olsson A., Hoglund K., Sjogren M., Andreasen N., Minthon L., Lannfelt L., et al. Measurement of alpha‐ and beta‐secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol 2003; 183: 74–80
   PubMed Web of Science ®Google Scholar
• Sennvik K., Fastbom J., Blomberg M., Wahlund L. O., Winblad B., Benedikz E. Levels of alpha‐ and beta‐secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 2000; 278: 169–72
   PubMedGoogle Scholar
• Vigo‐Pelfrey C., Lee D., Keim P., Lieberburg I., Schenk D. B. Characterization of beta‐amyloid peptide from human cerebrospinal fluid. J Neurochem 1993; 61: 1965–8
   PubMed Web of Science ®Google Scholar
• Wiltfang J., Esselmann H., Bibl M., Smirnov A., Otto M., Paul S., et al. Highly conserved and disease‐specific patterns of carboxyterminally truncated Abeta peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 2002; 81: 481–96
   PubMed Web of Science ®Google Scholar
• Hoglund K., Hansson O., Buchhave P., Zetterberg H., Lewczuk P., Londos E., et al. Prediction of Alzheimer's disease using a CSF pattern of C‐terminally truncated beta‐amyloid peptides. Neurodegener Dis. 2008, In press
   Google Scholar
• Mehta P. D., Pirttila T., Mehta S. P., Sersen E. A., Aisen P. S., Wisniewski H. M. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1–40 and 1–42 in Alzheimer disease. Arch Neurol 2000; 57: 100–5
   PubMedGoogle Scholar
• Schoonenboom N. S., Mulder C., Van Kamp G. J., Mehta S. P., Scheltens P., Blankenstein M. A., et al. Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?. Ann Neurol 2005; 58: 139–42
   PubMedGoogle Scholar
• Hansson O., Zetterberg H., Buchhave P., Andreasson U., Londos E., Minthon L., et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007; 23: 316–20
   PubMed Web of Science ®Google Scholar
• Simonsen A. H., Hansson S. F., Ruetschi U., McGuire J., Podust V. N., Davies H. A., et al. Amyloid beta1–40 quantification in CSF: comparison between chromatographic and immunochemical methods. Dement Geriatr Cogn Disord 2007; 23: 246–50
   PubMedGoogle Scholar
• Sergeant N., Bombois S., Ghestem A., Drobecq H., Kostanjevecki V., Missiaen C., et al. Truncated beta‐amyloid peptide species in pre‐clinical Alzheimer's disease as new targets for the vaccination approach. J Neurochem 2003; 85: 1581–91
   PubMed Web of Science ®Google Scholar
• Casas C., Sergeant N., Itier J. M., Blanchard V., Wirths O., van der Kolk N., et al. Massive CA1/2 neuronal loss with intraneuronal and N‐terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 2004; 165: 1289–300
   PubMed Web of Science ®Google Scholar
• Vanderstichele H., De Meyer G., Andreasen N., Kostanjevecki V., Wallin A., Olsson A., et al. Amino‐truncated {beta}‐amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem 2005; 51: 1650–60
   PubMed Web of Science ®Google Scholar
• Portelius E., Westman‐Brinkmalm A., Zetterberg H., Blennow K. Determination of beta‐amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation‐mass spectrometry. J Proteome Res 2006; 5: 1010–16
   PubMed Web of Science ®Google Scholar
• Portelius E., Zetterberg H., Andreasson U., Brinkmalm G., Andreasen N., Wallin A., et al. An Alzheimer's disease‐specific beta‐amyloid fragment signature in cerebrospinal fluid. Neurosci Lett 2006; 409: 215–19
   PubMed Web of Science ®Google Scholar
• Portelius E., Tran A. J., Andreasson U., Persson R., Brinkmalm G., Zetterberg H., et al. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res. 2007, In press
   Google Scholar
• Bateman R. J., Munsell L. Y., Morris J. C., Swarm R., Yarasheski K. E., Holtzman D. M. Human amyloid‐beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006; 12: 856–61
   PubMed Web of Science ®Google Scholar